Kelly Ray Knight

Kelly Ray Knight

Auto-generated profile, based on publicly available information

Kelly Ray Knight

University of California, San Francisco, San Francisco, CA, United States

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in International Journal of Drug Policy
Verified
Journal Article
Closed access
KKKelly R. Knight
Kelly R. Knight
ALAndrea M. Lopez
Andrea M. Lopez
MCMegan Comfort
Megan Comfort
MSMartha Shumway
Martha Shumway
JCJennifer Cohen
Jennifer Cohen
ERElise D. Riley
Elise D. Riley

1 August 2017 in Social Science & Medicine
Verified
Journal Article
Closed access
KKKelly R. Knight
Kelly R. Knight
MKMargot Kushel
Margot Kushel
JCJamie S. Chang
Jamie S. Chang
KZKara Zamora
Kara Zamora
RCRachel Ceasar
Rachel Ceasar
CMChristine Miaskowski
Christine Miaskowski

1 January 2022 in Substance Abuse
Verified
Journal Article
Open access
LSLeslie W. Suen
Leslie W. Suen
SCStacy Castellanos
Stacy Castellanos
NJNeena Joshi
Neena Joshi
SSShannon Satterwhite
Shannon Satterwhite
KKKelly R. Knight
Kelly R. Knight
Background: Prior to the COVID-19 pandemic, the United States (US) was already facing an epidemic of opioid overdose deaths. Overdose deaths continued to surge during the pandemic. To limit COVID-19 spread and to avoid disruptions in access to medications for opioid use disorder (MOUD), including buprenorphine and methadone, US federal and state agencies granted unprecedented exemptions to existing MOUD guidelines for Opioid Treatment Programs (OTPs), including loosening criteria for unsupervised take-home doses. We conducted a qualitative study to evaluate the impact of these policy changes on MOUD treatment experiences for providers and patients at an OTP in California. Methods: We interviewed 10 providers (including two physicians, five social worker associates, and three nurse practitioners) and 20 patients receiving MOUD. We transcribed, coded, and analyzed all interviews to identify emergent themes. Results: Patient participants were middle-aged (median age 51 years) and were predominantly men (53%). Providers discussed clinical decision-making processes and experiences providing take-homes. Implementation of expanded take-home policies was cautious. Providers reported making individualized decisions, using patient factors to decide if benefits outweighed risks of overdose and misuse. Decision-making factors included patient drug use, overdose risk, housing status, and vulnerability to COVID-19. New patient groups started receiving take-homes and providers noted few adverse events. Patients who received take-homes reported increased autonomy and treatment flexibility, which in turn increased likelihood of treatment stabilization and engagement. Patients who remained ineligible for take-homes, usually due to ongoing non-prescribed opioid or benzodiazepine use, desired greater transparency and shared decision-making. Conclusion: Federal exemptions in response to COVID-19 led to the unprecedented expansion of access to MOUD take-homes within OTPs. Providers and patients perceived benefits to expanding access to take-homes and experienced few adverse outcomes, suggesting expanded take-home policies should remain post-COVID-19. Future studies should explore whether these findings are generalizable to other OTPs and assess larger samples to quantify patient-level outcomes resulting from expanded take-home policies.

22 December 2020 in Global Public Health
Verified
Journal Article
Closed access
MHMichael Harvey
Michael Harvey
JNJoshua Neff
Joshua Neff
KKKelly R. Knight
Kelly R. Knight
JMJoia S. Mukherjee
Joia S. Mukherjee
SSSriram Shamasunder
Sriram Shamasunder
SHSeth M. Holmes
Seth M. Holmes
Structural competency is a new curricular framework for training health professionals to recognise and respond to disease and its unequal distribution as the outcome of social structures, such as economic and legal systems, healthcare and taxation policies, and international institutions. While extensive global health research has linked social structures to the disproportionate burden of disease in the Global South, formal attempts to incorporate the structural competency framework into US-based global health education have not been described in the literature. This paper fills this gap by articulating five sub-competencies for structurally competent global health instruction. Authors drew on their experiences developing global health and structural competency curricula—and consulted relevant structural competency, global health, social science, social theory, and social determinants of health literatures. The five sub-competencies include: (1) Describe the role of social structures in producing and maintaining health inequities globally, (2) Identify the ways that structural inequalities are naturalised within the field of global health, (3) Discuss the impact of structures on the practice of global health, (4) Recognise structural interventions for addressing global health inequities, and (5) Apply the concept of structural humility in the context of global health.

8 March 2021 in Substance Abuse
Verified
Journal Article
Closed access
NMNicky J Mehtani
Nicky J Mehtani
JRJessica T. Ristau
Jessica T. Ristau
HSHannah Snyder
Hannah Snyder
CSColleen Surlyn
Colleen Surlyn
JEJoanna Eveland
Joanna Eveland
KKKelly R. Knight
Kelly R. Knight
Background: COVID-19 has exacerbated income inequality, structural racism, and social isolation—issues that drive addiction and have previously manifested in the epidemic of opioid-associated overdose. The co-existence of these epidemics has necessitated care practice changes, including the use of telehealth-based encounters for the diagnosis and management of opioid use disorder (OUD). Methods: We describe the development of the “Addiction Telehealth Program” (ATP), a telephone-based program to reduce treatment access barriers for people with substance use disorders staying at San Francisco's COVID-19 Isolation and Quarantine (I&Q) sites. Telehealth encounters were documented in the electronic medical record and an internal tracking system for the San Francisco Department of Public Health (SFDPH) COVID-19 Containment Response. Descriptive statistics were collected on a case series of patients initiated on buprenorphine at I&Q sites and indicators of feasibility were measured. Results: Between April 10 and May 25, 2020, ATP consulted on the management of opioid, alcohol, GHB, marijuana, and stimulant use for 59 I&Q site guests. Twelve patients were identified with untreated OUD and newly prescribed buprenorphine. Of these, all were marginally housed, 67% were Black, and 58% had never previously been prescribed medications for OUD. Four self-directed early discharge from I&Q—1 prior to and 3 after initiating buprenorphine. Of the remaining 8 patients, 7 reported continuing to take buprenorphine at the time of I&Q discharge and 1 discontinued. No patients started on buprenorphine sustained significant adverse effects, required emergency care, or experienced overdose. Conclusions: ATP demonstrates the feasibility of telephone-based management of OUD among a highly marginalized patient population in San Francisco and supports the implementation of similar programs in areas of the U.S. where access to addiction treatment is limited. Legal changes permitting the prescribing of buprenorphine via telehealth without the requirement of an in-person visit should persist beyond the COVID-19 public health emergency.

8 October 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DPDereck W. Paul
Dereck W. Paul
KKKelly R. Knight
Kelly R. Knight
ACAndre Campbell
Andre Campbell
LALouise Aronson
Louise Aronson
Medicine has reached a new consciousness of the depth and devastation of racism in the United States. Amid a national-turned-global reckoning on racism in the spring of 2020, medical institutions and associations have declared en masse that structural racism and police violence are critical public health issues. But to go beyond declarations and move forward with fighting racism in medicine, we must understand the racial biases in our responses to past and present public health issues and plot an ethically and structurally different path to a new future.